Prolonged activity of factor IX as a monomeric Fc fusion protein.
about
New developments in the management of moderate-to-severe hemophilia BEmerging and future therapies for hemophiliaFuture of coagulation factor replacement therapyFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsReprogramming cells with synthetic proteinsAnimal models of hemophiliaFc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasNeonatal Fc receptor and IgG-based therapeuticsLessons Learned from Animal Models of Inherited Bleeding Disorders.Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in miceRecombinant FIXFc: a novel therapy for the royal disease?Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Treatment of hemophilia B: focus on recombinant factor IX.A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Antibody-based therapeutics to watch in 2011.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.Soluble monomeric IgG1 Fc.New treatments in hemophilia: insights for the clinician.Engineering Factor Viii for Hemophilia Gene Therapy.Pharmacokinetics of recombinant bifunctional fusion proteins.Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.Systemic delivery of factor IX messenger RNA for protein replacement therapyTargeted introduction and effective expression of hFIX at the AAVS1 locus in mesenchymal stem cellsNovel drugs to treat hemophilia.Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product.Clinical advances in hemophilia management.Joint protection in haemophilia.The hope and reality of long-acting hemophilia products.Haemophilia B: current pharmacotherapy and future directions.The future of hemostasis management.Will gene therapy trump factor treatment in hemophilia?
P2860
Q26751323-1B11246E-8D3D-4D3D-84C2-2829DF5EDEB9Q26781143-6A135CD9-E31B-4BD6-AB7D-C52F0C548AE0Q26820824-B1561664-BEFB-4A1F-8851-02EC12D27FE7Q26822421-3B212CD5-9893-42F3-8655-30534E65DC3CQ26853155-18D3F690-E303-44CF-BEA0-DC84DDAB470FQ27012571-461ED12F-67E4-4941-8D43-82932042A17DQ27014771-C13AD521-4333-4407-A608-D531C08F4050Q28252134-5A8F01FB-CFD5-4ABD-83DA-458EE9AEA643Q30409863-16B68627-D428-48DA-8650-B9859CB17922Q33631378-462A5B90-EB63-4A6C-849F-14EE63A5AB2CQ33917215-02AD459B-FA13-4028-B442-8AD2A34F3DCFQ33968782-7A048BE1-D882-449F-B075-1B02FF2B2A98Q34045763-B6A2F02E-20E8-485A-AD6C-D664E6CD313DQ34329068-0A1C3BA2-C764-4ED3-8DE0-94A2B7BDD008Q34557556-5C32BE0F-FE0C-4820-989D-24BD53A45F08Q34570079-784CAB4A-7BA1-4C42-8C14-8D6B1F3314E5Q35565320-3AE61E75-BCC2-4DC7-86A1-AC6FCFCC4F35Q35612397-0E58B184-4C6E-404C-973A-C7627FC2EFF2Q35692016-F68B025D-9522-4251-9D4D-594332360324Q35779980-0162F1F3-2BEC-4A98-BBEA-9C9F7AA48905Q35913495-440459E5-2918-4FA5-8EF6-0D2F5944CF13Q36003820-F4A1D584-C067-4B6C-8B10-CBF90A51517AQ36612681-0FE6021B-07E2-467B-BF50-7FF315A2E3C5Q36737263-F214424A-E44A-4061-983D-13303CF348BBQ37033032-DF33727E-5DD7-41AA-8DEE-F525B6424301Q37342834-84F77F78-D9A7-4C23-8259-AF19DCE96706Q37494846-642250C0-9699-45E0-B09A-EF2EC5E3C453Q37591452-7745B5DE-5669-42EC-958C-8A0AF2D4ACD6Q37623821-3A4C11C3-D95F-4969-B646-3CEE5291B399Q37634856-A3865610-4F4D-4EE6-AFE6-86B10721D069Q37695999-E0767B5F-9906-41EB-BFEA-ADDDA01F76D0Q37722108-01A3155F-76F4-45C7-8428-7FE6F05E672DQ37775029-C1472101-B97B-4BEF-81E4-9E16614A7805Q37872258-535225AB-0D7D-4171-99AA-E8919F51C01AQ37900933-AAE11B96-BC7E-4B47-94D0-05218931B13DQ37912258-43036F71-622E-4BFF-8CDF-05B3931514C9Q37990479-A3689F59-07DE-4397-A539-4574974CC0D8Q38040458-917D09F8-4973-4FFC-A51F-BA69FF286AFCQ38056457-0B0BF254-E98E-4125-ACA1-1A0BF8401F82Q38078426-7F70C1B0-F9B1-42C9-8993-E4EC754272C3
P2860
Prolonged activity of factor IX as a monomeric Fc fusion protein.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@en
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@nl
type
label
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@en
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@nl
prefLabel
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@en
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@nl
P2093
P1433
P1476
Prolonged activity of factor IX as a monomeric Fc fusion protein.
@en
P2093
Alan J Bitonti
Elizabeth P Merricks
George D Kamphaus
Greg Zarbis-Papastoitsis
Jennifer A Dumont
John V Amari
Robert T Peters
Susan C Low
Thomas J Reidy
P304
P356
10.1182/BLOOD-2009-08-239665
P407
P577
2010-01-07T00:00:00Z